Trial Profile
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax (V-RBAC) in High-risk Elderly Patients With Mantle Cell Lymphoma (MCL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Bendamustine; Cytarabine; Rituximab
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 12 Dec 2023 Results assessing safety and efficacy of Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 26 Jul 2021 Status changed from recruiting to active, no longer recruiting.
- 16 Mar 2021 Planned primary completion date changed from 1 Feb 2021 to 1 Mar 2021.